| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002868 | *ST绿康 | 27.16 | -1.95% | 7419.5 | 2024.76万 | | 920275 | 驱动力 | 9.41 | -1.67% | 1.23万 | 1167.29万 | | 688098 | 申联生物 | 10.36 | -0.67% | 4.77万 | 4950.32万 | | 920729 | 永顺生物 | 9.41 | 0.64% | 1.40万 | 1329.44万 | | 002688 | 金河生物 | 6.84 | 1.03% | 17.68万 | 1.21亿 | | 603718 | 海利生物 | 6.90 | 1.32% | 6.73万 | 4637.75万 | | 600195 | 中牧股份 | 7.27 | 1.54% | 8.37万 | 6066.24万 | | 688526 | 科前生物 | 17.86 | 1.59% | 3.72万 | 6626.71万 | | 603566 | ...

证券之星消息，10月9日动物保健板块较上一交易日上涨0.01%，驱动力领涨。当日上证指数报收于 3933.97，上涨1.32%。深证成指报收于13725.56，上涨1.47%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920275 | 驱动力 | 9.57 | 1.38% | 1.76万 | 1 1627.05万 | | | 002688 | 金河生物 | 6.77 | 1.20% | 18.34万 | + 1.23亿 | | | 600201 | 生物股份 | 9.73 | 0.93% | 47.05万 | | 4.52亿 | | 300871 | 回盛生物 | 20.90 | 0.87% | 4.16万 | 8621.63万 | | | 603566 | 普莱柯 | 13.82 | 0.58% | 4.15万 | 5689.70万 | | | 603718 | 海利生物 | 6.81 | 0.15% | 5.47万 | 3717.77万 | ...

Core Viewpoint - The animal health sector experienced a rise of 0.98% on September 30, with *ST Lvkang leading the gains, while the overall market indices also showed positive movement [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3882.78, up 0.52% [1]. - The Shenzhen Component Index closed at 13526.51, up 0.35% [1]. - The animal health sector's individual stock performance is detailed in a table, highlighting various stocks' closing prices and percentage changes [1]. Group 2: Stock Performance - *ST Lvkang (002868) closed at 28.01, with a gain of 3.51% and a trading volume of 16,700 shares, amounting to approximately 46.61 million yuan [1]. - Other notable stocks include: - Biological Shares (600201) at 9.64, up 1.69% with a trading volume of 412,400 shares [1]. - Jinhe Biological (002688) at 6.69, up 1.67% with a trading volume of 150,600 shares [1]. - KQ Bio (688526) at 17.72, up 1.37% with a trading volume of 32,700 shares [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 3.40 million yuan from institutional investors, while retail investors experienced a net outflow of 28.01 million yuan [2][3]. - The detailed capital flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3]. - For instance, Biological Shares (600201) had a net inflow of approximately 19.60 million yuan from institutional investors, while *ST Lvkang (002868) faced a net outflow of about 6.49 million yuan [3].

Core Insights - The animal health sector experienced a slight increase of 0.46% on September 29, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Stock Performance - Shenlian Biological (688098) closed at 10.59, up 1.92% with a trading volume of 68,700 shares and a turnover of 72.32 million yuan [1] - Other notable performers included: - Biological Shares (600201) at 9.48, up 1.50% with a turnover of 503 million yuan [1] - Pulaike (603566) at 13.78, up 1.03% with a turnover of 54.30 million yuan [1] - Zhongmu Shares (600195) at 7.12, up 0.85% with a turnover of 49.02 million yuan [1] Capital Flow - The animal health sector saw a net outflow of 7.69 million yuan from institutional investors, while retail investors contributed a net inflow of 8.08 million yuan [2] - The detailed capital flow for key stocks includes: - Shenlian Biological: net outflow of 5.50 million yuan from retail investors [3] - Biological Shares: net outflow of 7.67 million yuan from retail investors [3] - Pulaike: net outflow of 4.08 million yuan from retail investors [3]

Group 1 - The core point of the article is that Xianfeng Holdings announced the decision to exit the feed business through the termination of agreements with various companies [1] - The company’s subsidiary, Zunyi Kangxiyuan Animal Nutrition Technology Co., Ltd., has signed a lease contract and sales agreements with several entities, which are now being terminated [1] - The decision was made after friendly negotiations among the parties involved, and the transition will be completed gradually after the agreements are signed [1]

Group 1 - The company, Xianfeng Holdings (002141), announced on the evening of September 26 that it and its controlling subsidiaries have no overdue guarantees, no guarantees involved in lawsuits, and no guarantees that it should bear due to being judged to lose a lawsuit [1]

Core Viewpoint - The animal health sector experienced a rise of 1.59% on September 26, with Bio-Pharmaceuticals leading the gains, while the overall market indices, Shanghai Composite and Shenzhen Component, saw declines of 0.65% and 1.76% respectively [1] Group 1: Market Performance - The animal health sector's individual stock performance showed significant variations, with Bio-Pharmaceuticals closing at 9.34, up by 7.23%, and a trading volume of 1.0367 million shares, resulting in a turnover of 973 million yuan [1] - Other notable performers included Huisheng Biological at 20.68, up by 1.87%, and Ruipu Biological at 20.93, up by 1.60% [1] Group 2: Capital Flow - The animal health sector saw a net inflow of 86.5157 million yuan from institutional investors, while retail investors experienced a net outflow of 44.7995 million yuan [2] - The capital flow data indicates that major stocks like Bio-Pharmaceuticals had a net inflow of 12.63% from institutional investors, despite a significant outflow from retail and speculative investors [3]

Group 1 - The core point of the article is that Xianfeng Holdings announced its total guarantee amount and the composition of its revenue for the first half of 2025, highlighting its financial stability and business segments [1] Group 2 - As of the announcement, the total guarantee amount provided by the company and its subsidiaries is 140 million yuan, which accounts for 17.07% of the latest audited net assets [1] - The total balance of guarantees provided to off-balance sheet entities is 20 million yuan, representing 2.44% of the latest audited net assets [1] - The company and its subsidiaries have no overdue guarantees, litigation-related guarantees, or guarantees due to adverse judgments [1] Group 3 - For the first half of 2025, the revenue composition of Xianfeng Holdings is as follows: electronic materials account for 57.48%, feed accounts for 35.4%, other products account for 3.92%, and bioproducts account for 3.2% [1] - The current market capitalization of Xianfeng Holdings is 3.9 billion yuan [1]

Group 1 - The core point of the article is that Xianfeng Holdings (002141.SZ) announced its subsidiary, Zunyi Kangxiyuan Animal Nutrition Technology Co., Ltd. (referred to as "Kangxiyuan"), plans to exit the feed business by terminating existing agreements with related parties [1] - Kangxiyuan has previously signed a feed factory lease contract with Zunyi Riquan Feed Biotechnology Co., Ltd. and its shareholder, Guangdong Tiannong Group Co., Ltd., along with feed purchase and sales agreements with several other companies [1] - The company's board of directors has authorized the chairman or a designated agent to sign the termination agreements and handle subsequent matters related to the exit from the feed business [1]

关于为控股子公司向银行借款事项 提供担保和反担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 （一）担保情况 贤丰控股股份有限公司 证券代码：002141 证券简称：贤丰控股 公告编号：2025-074 因业务发展需要，贤丰控股股份有限公司（简称"公司"）的控股子公司成 都史纪生物制药有限公司（以下简称"史纪生物"）拟通过自身及担保公司向银 行申请不超过人民币 2,000 万元的流动资金借款，公司、史纪生物就史纪生物借 款事项提供担保和反担保。具体如下： 1. 担保事项一：史纪生物拟向成都农村商业银行股份有限公司龙泉驿洪河 分理处申请 800 万元流动资金借款，借款期限 1 年，借款利率以银行借款合同为 准。成都小企业融资担保有限责任公司（以下简称："担保公司"）就该笔借款 为史纪生物提供连带责任保证担保，史纪生物以其持有房产提供抵押担保和反担 保。基于上述借款及担保情况，公司为担保公司提供反担保，担保金额 800 万元， 保证方式为不可撤销的连带反担保保证责任。 2. 担保事项二：史纪生物拟向成都银行龙泉驿支行申请 800 万元流 ...